Search

Sanofi SA

Closed

SectorHealthcare

85.15 -1.4

Overview

Share price change

24h

Current

Min

84.56

Max

86.36

Key metrics

By Trading Economics

Income

1.1B

2.9B

Sales

129M

11B

P/E

Sector Avg

16.819

37.003

EPS

2.91

Profit margin

27.303

Employees

82,878

EBITDA

-881M

1.9B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+21.66% upside

Market Stats

By TradingEconomics

Market Cap

3.3B

107B

Previous open

86.55

Previous close

85.15

News Sentiment

By Acuity

27%

73%

64 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

29 Oct 2025, 11:21 UTC

Earnings

Santander's U.S. Bet Starts to Pay Off as Profit Reaches Record -- Update

29 Oct 2025, 06:35 UTC

Earnings

Santander Profit Rises on Contained Costs

24 Oct 2025, 08:29 UTC

Earnings

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

24 Oct 2025, 07:00 UTC

Earnings

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

15 Oct 2025, 07:48 UTC

Acquisitions, Mergers, Takeovers

Santander Merges European Consumer-Finance Businesses

8 Oct 2025, 08:42 UTC

Major Market Movers

U.K. Bank Shares Rise After Regulator Softens Car-Loan Redress Estimate

29 Oct 2025, 05:56 UTC

Earnings

Analysts Saw Santander 3Q Net Interest Income EUR11.17B

29 Oct 2025, 05:56 UTC

Earnings

Santander 3Q Net Interest Income EUR11.10B

29 Oct 2025, 05:55 UTC

Earnings

Santander 3Q RoTE 16.9%

29 Oct 2025, 05:51 UTC

Earnings

Santander Backs 2025 View

29 Oct 2025, 05:50 UTC

Earnings

Analysts Saw Santander 3Q Loan Loss Provisions EUR3.00B

29 Oct 2025, 05:50 UTC

Earnings

Santander 3Q Loan Loss Provisions EUR2.93B

29 Oct 2025, 05:50 UTC

Earnings

Analysts Saw Santander 3Q Rev EUR15.30B

29 Oct 2025, 05:50 UTC

Earnings

Santander 3Q Rev EUR15.27B

29 Oct 2025, 05:49 UTC

Earnings

Analysts Saw Santander End-3Q CET1 Ratio 13.07%

29 Oct 2025, 05:49 UTC

Earnings

Santander End-3Q CET1 Ratio 13.1%

29 Oct 2025, 05:48 UTC

Earnings

Analysts Saw Santander 3Q Net Pft EUR3.43B

29 Oct 2025, 05:48 UTC

Earnings

Santander 3Q Net Pft EUR3.50B

24 Oct 2025, 08:21 UTC

Market Talk
Earnings

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24 Oct 2025, 07:56 UTC

Market Talk
Earnings

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

24 Oct 2025, 05:30 UTC

Earnings

Sanofi 3Q Adj EPS EUR2.91

24 Oct 2025, 05:30 UTC

Earnings

Sanofi Backs 2025 View

24 Oct 2025, 05:30 UTC

Earnings

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

24 Oct 2025, 05:30 UTC

Earnings

Sanofi 3Q Business Net Profit at EUR3.55B

24 Oct 2025, 05:30 UTC

Earnings

Analysts Saw Sanofi 3Q Adjusted EPS at EUR2.70

24 Oct 2025, 05:30 UTC

Earnings

Sanofi: Dupixent Sales Up 26% to EUR4.16B

24 Oct 2025, 05:30 UTC

Earnings

Sanofi 3Q Net Pft EUR2.80B

24 Oct 2025, 05:30 UTC

Earnings

Analysts Saw Sanofi 3Q Net Sales at EUR12.29B

24 Oct 2025, 05:30 UTC

Earnings

Sanofi 3Q Sales EUR12.43B

17 Oct 2025, 07:57 UTC

Market Talk
Acquisitions, Mergers, Takeovers

BBVA Shares Jump, Defying Bank Losses, After Sabadell Offer Fails -- Market Talk

Sanofi SA Forecast

Price Target

By TipRanks

21.66% upside

12 Months Forecast

Average 105.003 EUR  21.66%

High 119 EUR

Low 95 EUR

Based on 14 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

12

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

91.3 / 96.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

64 / 373 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat